



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 10.11.2023

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070.

Dear Sir,

Sub: outcome of the Board Meeting held today i.e., on 10th November, 2023 - Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e. Friday, 10th November, 2023 had inter-alia transacted and approved the following items of business:

1. Approved the Un-audited Financial Results long with the Segment results for the quarter and half year ended 30th September, 2023.
2. Approved the Statement of Assets and Liabilities as at 30th September, 2023.
3. Approved the Cash Flow Statement as at 30th September, 2023.

We herewith enclose the following:

- A. Un-Audited financial Results, Segment Results, the Statement of Assets and Liabilities and Cash Flow statement as at 30th September, 2023.
- B. Limited Review Report of the Statutory Auditors for the quarter and half year ended 30th September, 2023.

Kindly take the above on your records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(S. Lekha Sai)
Company Secretary

The meeting Commenced at 4:00 PM
The Meeting Concluded at 6:00 PM

SIGACHI LABORATORIES LIMITED

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For The Quarter and Half Year ended 30th September, 2023

(Rs.in Lakhs)

| Sl.No | Particulars | Quarter ended | | | Half - year ended | | Year ended |
|-------|--|---------------|-------------|-------------|-------------------|-------------|------------|
| | | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| | Income | | | | | | |
| 1 | Revenue from operations | 87.28 | 100.96 | 64.26 | 188.24 | 101.47 | 194.70 |
| 2 | Other income | 22.52 | 9.62 | 13.99 | 32.14 | 20.96 | 50.26 |
| 3 | Total Income (1+2) | 109.80 | 110.58 | 78.25 | 220.38 | 122.43 | 244.96 |
| 4 | Expenses | | | | | | |
| | a) Cost of materials consumed | - | - | - | - | - | - |
| | b) Purchase of Stock-in-Trade | - | - | - | - | - | - |
| | c) Impairment on Advances | 75.00 | - | - | 75.00 | - | - |
| | d) Fair Value Loss | - | - | (39.59) | - | - | - |
| | e) Employee benefits expense | 10.11 | 9.56 | 9.31 | 19.67 | 17.70 | 35.79 |
| | f) Finance costs | - | - | - | - | - | - |
| | g) Depreciation and amortization expense | 5.80 | 5.00 | 4.61 | 10.80 | 8.84 | 18.88 |
| | h) Other expenses | 3.22 | 4.19 | 3.73 | 7.41 | 7.57 | 17.05 |
| | Total Expenses | 94.13 | 18.75 | (21.94) | 112.88 | 34.11 | 71.72 |
| 5 | Profit/(Loss) before exceptional items and tax (3-4) | 15.67 | 91.83 | 100.19 | 107.50 | 88.32 | 173.24 |
| 6 | Exceptional Items | - | - | - | - | - | - |
| 7 | Profit/(Loss) before tax (5-6) | 15.67 | 91.83 | 100.19 | 107.50 | 88.32 | 173.24 |
| 8 | Tax expense | | | | | | |
| | (a) Current tax | 11.13 | 6.45 | 10.48 | 17.58 | 18.91 | 46.45 |
| | (b) Deferred tax | 2.36 | 9.97 | 10.44 | 12.33 | (4.24) | (4.21) |
| | Total Tax Expense | 13.49 | 16.42 | 20.92 | 29.91 | 14.67 | 42.24 |
| 9 | Profit/(Loss) for the Period (7-8) | 2.18 | 75.41 | 79.27 | 77.59 | 73.65 | 131.00 |
| 10 | Other Comprehensive income (OCI) | | | | | | |
| | (a) Items that will not be reclassified to profit or loss | 88.26 | 141.82 | 60.50 | 230.08 | (52.49) | (31.97) |
| | (b) Remeasurement gains/(losses) on defined benefit plans | - | - | - | - | - | 0.14 |
| | Tax on Items that will not be reclassified to profit or loss | (9.18) | (14.75) | - | (23.93) | - | - |
| | (c) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | Total Other Comprehensive income | 79.08 | 127.07 | 60.50 | 206.15 | (52.49) | (31.83) |
| | Total Comprehensive income (9+10) | 81.26 | 202.48 | 139.77 | 283.74 | 21.16 | 99.17 |
| 11 | Paid-up Equity Share Capital (Face Value Rs.10/- per share) | 675.31 | 675.31 | 675.31 | 675.31 | 675.31 | 675.31 |
| 12 | Other Equity | - | - | - | - | - | 2,342.90 |
| 13 | Earnings per equity share (of Rs.10/- each) (not annualized) (Rs.) | | | | | | |
| | (1) Basic | 0.03 | 1.12 | 1.17 | 1.15 | 1.09 | 1.94 |
| | (2) Diluted | 0.03 | 1.12 | 1.17 | 1.15 | 1.09 | 1.94 |

Segment wise Revenue, Results and Capital Employed for the Quarter and Half year ended 30th September, 2023

(Rs.in Lakhs)

| Sl.No | Particulars | Quarter ended | | | Half - year ended | | Year ended |
|-------|--|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|
| | | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Segment Revenue | | | | | | |
| | a) Bulk Drugs and Intermediates (Lease Rents) | 33.00 | 22.00 | 31.50 | 55.00 | 52.50 | 128.50 |
| | b) Investments | 76.80 | 88.58 | 86.34 | 165.38 | 69.93 | 116.46 |
| | Total | 109.80 | 110.58 | 117.84 | 220.38 | 122.43 | 244.96 |
| | Less: Inter Segment Revenue | - | - | - | - | - | - |
| | Net Sales/Income from Operations | 109.80 | 110.58 | 117.84 | 220.38 | 122.43 | 244.96 |
| 2 | Segment Results Profit/(Loss) before tax and finance Costs from each segment | | | | | | |
| | a) Bulk Drugs and Intermediates (Lease Rents) | 27.02 | 16.55 | 26.76 | 43.57 | 43.02 | 107.69 |
| | b) Investments | 76.80 | 88.58 | 86.34 | 165.38 | 69.93 | 116.46 |
| | Total | 103.82 | 105.13 | 113.10 | 208.95 | 112.95 | 224.15 |
| | Less: (i) Finance Costs | - | - | - | - | - | - |
| | (ii) Other Un-allocable Expenditure net off | 88.15 | 13.30 | 12.91 | 101.45 | 24.63 | 50.91 |
| | (iii) Un-allocable income | - | - | - | - | - | - |
| | Total Profit Before Tax | 15.67 | 91.83 | 100.19 | 107.50 | 88.32 | 173.24 |
| 3 | Capital Employed | | | | | | |
| | (Segment Assets – Segment Liabilities) | | | | | | |
| | a) Bulk Drugs and Intermediates | 899.22 | 899.91 | 698.14 | 899.22 | 698.14 | 894.97 |
| | b) Investments | 2,458.48 | 2,376.53 | 2,297.82 | 2,458.48 | 2,297.82 | 2,178.99 |
| | Total | 3,357.70 | 3,276.44 | 2,995.96 | 3,357.70 | 2,995.96 | 3,073.96 |

Notes :

- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- The above unaudited financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their respective meeting(s) held on 10th November 2023.
- The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- These Financial Results are available on the Stock Exchange website (www.mse.i.in) and also on the company's website at (www.sllab.com).
- Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation.

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
Date : 10.11.2023

(T.R.Sekhar)
Executive Director
DIN:02943146

SIGACHI LABORATORIES LIMITED
 Regd.Office: S.No: 530 & 534, Bonthapally - 502 313.
 Gummadidala Mandal, Sanga Reddy District, Telangana.
 Tel No.: 040 - 23204230 / 23204273
 Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in
 CIN:L24230TG1994PLC018786
 Statement of Assets and Liabilities as at 30th September, 2023

(Rs.in Lakhs)

| Particulars | As at 30.09.2023 | As at 31.03.2023 |
|--|------------------|------------------|
| | Un - Audited | Audited |
| A. ASSETS | | |
| 1. Non-Current Assets | | |
| (a) Property Plant and Equipment | 329.48 | 236.71 |
| (b) Financial Assets | | |
| (i) Investments | 2,391.22 | 1,957.24 |
| (ii) Other Financial Assets | 43.62 | 43.53 |
| (c) Other non Current Assets | 470.50 | 285.50 |
| Total Non - Current Assets | 3,234.82 | 2,522.98 |
| 2. Current Assets | | |
| (a) Financial Assets | | |
| (i) Investments | - | 9.04 |
| (ii) Trade Receivables | 31.55 | 0.76 |
| (iii) Cash and Cash Equivalents | 181.98 | 371.25 |
| (iv) Other Financial Assets | 67.25 | 221.75 |
| (b) Other Current Assets | 1.05 | 0.11 |
| Total Current Assets | 281.83 | 602.91 |
| Total Assets | 3,516.65 | 3,125.89 |
| B. EQUITY AND LIABILITIES | | |
| 1. Equity | | |
| (a) Equity Share Capital | 731.06 | 731.06 |
| (b) Other Equity | 2,626.64 | 2,342.90 |
| Total Equity | 3,357.70 | 3,073.96 |
| 2. Liabilities | | |
| Non-Current Liabilities | | |
| (a) Financial Liabilities | - | - |
| (b) Long term Provisions | 6.71 | 6.71 |
| (c) Deferred Tax Liabilities (net) | 47.77 | 11.51 |
| (d) Other non - Current Liabilities | 25.00 | 25.00 |
| Total Non - Current Liabilities | 79.48 | 43.22 |
| Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | - | - |
| (ii) Trade Payables | - | - |
| (iii) Other Financial Liabilities | 5.79 | 6.43 |
| (b) Provisions | 0.39 | 2.28 |
| (c) Other Current Liabilities | 73.29 | - |
| Total Current Liabilities | 79.47 | 8.71 |
| Total Equity and Liabilities | 3,516.65 | 3,125.89 |

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
 Date : 10.11.2023

(T.R.Sekhar)
 Executive Director
 DIN:02943146

| Sigachi Laboratories Limited | | |
|--|---------------------------------------|----------------------------------|
| CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th SEPTEMBER, 2023 | | |
| (Rs. In Lakhs) | | |
| Particulars | For the half year Ended 30.09.2023 | For the year Ended 31.03.2023 |
| Cash Flows from Operating Activities | | |
| Profit before tax | 107.50 | 173.24 |
| Adjustments for : | | |
| Depreciation and amortization expenses | 10.80 | 18.88 |
| (Profit)/Loss on sale of Property, Plant and Equipment | (1.57) | - |
| Dividend Received | (19.61) | (41.75) |
| Provision for Gratuity & Leave Encashment | - | 0.97 |
| Provision for Impairment | 75.00 | - |
| (Profit)/Loss on sale of Investments | (0.65) | (1.50) |
| Bad Deposits Recovery | - | (0.09) |
| Interest | (31.92) | (73.05) |
| Fair Value (Gains)/Losses | (111.63) | (0.07) |
| Operating profit before working capital changes | 27.92 | 76.63 |
| Movements in Working Capital | | |
| (Increase)/Decrease in Trade Receivables | (30.78) | 15.12 |
| (Increase)/Decrease in Other Financial Assets | 154.50 | - |
| (Increase)/Decrease in Other Current Assets | 0.01 | (0.11) |
| (Increase)/Decrease in Other Non Current Assets | (260.00) | 0.52 |
| Increase/(Decrease) in Other Current Financial Liabilities | (0.64) | (0.25) |
| Increase/(Decrease) in Other Current Liabilities | 73.29 | - |
| (Increase)/Decrease in Other Non Current Financial Assets | (0.09) | 0.21 |
| Changes in Working Capital | (63.71) | 15.49 |
| Cash generated from operations | (35.79) | 92.12 |
| Direct Taxes Paid | 20.43 | 44.18 |
| Net Cash from operating activities (A) | (56.22) | 47.94 |
| Cash flows from Investing Activities | | |
| (Purchase) of Property, Plant and Equipment | (103.96) | (27.00) |
| Sale of Investments - Others | 9.04 | - |
| (Purchase) of Investments | (84.24) | (96.67) |
| Sale of Investments | 41.23 | 244.54 |
| Dividend Received | 19.61 | 41.75 |
| Bad Deposits Recovery | - | 0.09 |
| Proceeds From sale of Property, Plant and Equipment | 1.96 | - |
| Interest Received | 31.92 | 73.05 |
| (Increase)/Decrease in other term deposits | (48.61) | 6.89 |
| Net Cash used in Investing Activities (B) | (133.05) | 242.65 |
| Cash flows from/(used in) Financing Activities | | |
| Proceeds from Long term borrowings | - | - |
| Repayment/(Proceeds) of/from Short-term borrowings | - | - |
| Dividend paid | - | - |
| Net Cash used in Financing Activities (C) | - | - |
| Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C) | (189.27) | 290.59 |
| Cash and Cash Equivalents at the beginning of the year | 371.25 | 80.66 |
| Cash and Cash Equivalents at the ending of the year | 181.98 | 371.25 |

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
Date : 10.11.2023

(T.R.Sekhar)
Executive Director
DIN:02943146



Limited Review Report on Unaudited financial results of M/s Sigachi Laboratories Limited

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s Sigachi Laboratories Limited pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

TO THE BOARD OF DIRECTORS OF Sigachi Laboratories Limited

We have reviewed the accompanying unaudited financial results of **M/s Sigachi Laboratories Limited**, for the quarter ended 30 September 2023 and for the period from 1 April 2023 to 30 September 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Sigachi Laboratories Limited** as at 30 September 2023.

For NSVR & Associates LLP
Chartered Accountants
FRN: 008801S/S200060

V. Gangadhara Rao



V Gangadhara Rao
Partner
M. No.219486
UDIN: 23219486BGQCYW4567
Place: Hyderabad
Date: 10-11-2023.